Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.

Rhea-AI Summary

Scilex Holding Company (Nasdaq: SCLX) confirmed a Dream Bowl 2026 Meme Coin claim process tied to a December 24, 2025 distribution. Eligible shareholders of record as of November 25, 2025 may claim allocated tokens any time after the December 24, 2025 distribution using the designated process at www.dreambowlcoin.com. The token program is powered by Datavault AI using encrypted blockchain infrastructure and real-world asset tokenization. The announcement positions the meme coin as a fusion of sports, digital assets, and shareholder perks. For corporate and product information, Scilex directs investors to its corporate and product websites.

Positive

• Eligible shareholders of record on Nov 25, 2025 can claim tokens
• Distribution effective on Dec 24, 2025 with online claim process

Negative

• No token economic terms, supply, or valuation disclosed in the announcement
• No details on tax, trading, or shareholder record‑keeping implications provided

Key Figures

Record date November 25, 2025 Eligibility date for Dream Bowl 2026 Meme Coin distribution

Claim start date December 24, 2025 Date from which eligible shareholders may claim tokens

Datavault shares via warrant 263,914,094 shares Pre-funded warrant exercised by Scilex for Datavault common stock

Datavault stake value $583.3 million Value based on Datavault’s $2.21 close on Nov 25, 2025

Gross proceeds $20.3 million Cash raised from warrant exercises announced Nov 24–25, 2025

Non-recourse loan facility $100 million Maximum principal under loan and securities pledge agreement

Collateralization level 70% Portion of loan principal value covered by pledged Scilex shares

Market Reality Check

$13.26 Last Close

Volume Pre-news volume of 58,096 is below the 20-day average of 86,128 (relative volume 0.67). low

Technical Shares trade above the 200-day MA of $12.97 at a pre-news price of $14.27.

Peers on Argus

Peers show mixed moves, from -10.07% (CTOR) to +3.86% (IRWD), indicating no clear sector-wide trend aligned with SCLX’s modest -0.56% move pre-announcement.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 26	AI equity investment	Positive	+0.4%	Completed second tranche Datavault AI equity financing and exercised warrant.
Nov 25	Warrant exercise	Negative	-8.0%	Reduced-price warrant exercises raised $20.3M and issued new higher-strike warrant.
Nov 24	Warrant agreement	Negative	-2.3%	Definitive agreement for warrant cash exercise and new five-year warrant issuance.
Nov 21	Meme coin update	Positive	+18.8%	Update on Dream Bowl 2026 Meme Coin distribution mechanics and conditions.
Nov 11	Meme coin approval	Positive	+2.8%	Datavault AI board approved Dream Bowl 2026 Meme Coin distribution to holders.

Pattern Detected

Across recent financings and AI/Dream Bowl updates, price reactions have consistently aligned with news tone, with positive AI/coin items drawing strong upside.

Recent Company History

Over the past few months, Scilex has combined capital-raising with an expanding relationship with Datavault AI. Warrant exercises on Nov 24–25, 2025 raised about $20.3 million twice, while AI-tagged news focused on Datavault investment and the Dream Bowl 2026 Meme Coin distribution, including record dates and opt-in mechanics. These AI-related announcements have generally been met with positive price moves, framing today’s confirmation of the claim process as a continuation of that theme.

Market Pulse Summary

The stock moved -8.2% in the session following this news. A negative reaction despite confirmed shareholder perks would contrast with prior AI-tagged news, which produced an average move of 7.81% and included an 18.79% rise on a earlier meme coin update. Pressure could be influenced by financing overhang from warrant deals and the non-recourse loan secured by equity, where price and volume triggers in loan covenants may heighten sensitivity to downside moves.

Key Terms

blockchain technical

"Powered by Datavault AI’s patented, encrypted blockchain infrastructure"

A blockchain is a digital record-keeping system that securely stores information across many computers, making it difficult to alter or tamper with. Think of it like a shared, unchangeable ledger that everyone can see and verify, ensuring transparency and trust. For investors, this technology offers a way to securely track transactions and assets without relying on a central authority, potentially reducing costs and increasing security.

real-world asset (RWA) tokenization financial

"real-world asset (RWA) tokenization technologies, the Dream Bowl 2026 Meme Coin"

Real-world asset (RWA) tokenization is the process of creating digital tokens that represent ownership or economic rights in physical assets such as real estate, commodities, or loans. For investors it matters because tokenization can turn large, illiquid assets into many smaller, tradable pieces—like slicing a house into shares—making markets faster, cheaper and open to more participants, though legal recognition and custody rules still determine true value and risk.

digital assets financial

"fusion of sports, digital assets, and shareholder perks"

Digital assets are electronic files or representations of value stored electronically, such as cryptocurrencies, digital tokens, or digital art. They matter to investors because they can be bought, sold, and used for transactions much like physical assets, but exist entirely in digital form, offering new opportunities for investment and financial innovation.

cardiometabolic medical

"chronic pain and neurodegenerative and cardiometabolic disease"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced confirmed Dream Bowl 2026 Meme Coins claim process on December 24, 2025.

Powered by Datavault AI’s patented, encrypted blockchain infrastructure and real-world asset (RWA) tokenization technologies, the Dream Bowl 2026 Meme Coin represents a pioneering fusion of sports, digital assets, and shareholder perks. Eligible shareholders of record as of November 25, 2025, may claim their allocated tokens at any time following December 24, 2025, distribution date through the designated process outlined at www.dreambowlcoin.com.

For more information on Scilex Holding Company, refer to www.scilexholding.com.

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com.

For more information on ZTlido^® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB^®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba^®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Datavault AI’s distribution of the Dream Bowl 2026 Meme Coin and the timing thereof, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; risks related to legal proceedings that may be instituted against the parties regarding the Dream Bowl 2026 Meme Coin and the distribution thereof to holders of Scilex common stock; the risks associated with the right of the Board of Directors of Datavault AI to change the record date (and, as a result, the payment date) of the distribution of, and/or to revoke, the Dream Bowl 2026 Meme Coin; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

FAQ

Who is eligible to claim Dream Bowl 2026 Meme Coins from SCLX?

Shareholders of record as of November 25, 2025 are eligible to claim allocated tokens.

When can SCLX shareholders claim Dream Bowl 2026 Meme Coins?

Allocated tokens may be claimed at any time following the December 24, 2025 distribution date.

Where do SCLX shareholders claim their Dream Bowl 2026 Meme Coins?

Claims are processed through the designated website: www.dreambowlcoin.com.

What technology powers the Dream Bowl 2026 Meme Coin distributed by SCLX?

The token is powered by Datavault AI using encrypted blockchain infrastructure and RWA tokenization.

Does the SCLX announcement disclose the token supply or valuation for Dream Bowl 2026?

No; the announcement does not provide token supply, valuation, or economic terms.